Evaluation of TrkB and BDNF transcripts in prefrontal cortex, hippocampus, and striatum from subjects with schizophrenia, bipolar disorder, and major depressive disorder

Neurobiology of Disease

Volumn 77, Issue , 2015, Pages 220-227

  Reinhart, Veronica ^a   Bove, Susan E ^b   Volfson, Dmitri ^a   Lewis, David A ^c   Kleiman, Robin J ^d   Lanz, Thomas A ^a  

^a PFIZER INC   (United States)

^b Life Technologies   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

BDNF; Bipolar disorder; Postmortem; RT PCR; Schizophrenia; TrkB

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; KAINIC ACID; MESSENGER RNA; MEMBRANE PROTEIN; PROTEIN TYROSINE KINASE; TROPOMYOSIN-RELATED KINASE-B, HUMAN;

ADULT; AGE; AMINO ACID BRAIN LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BDNF GENE; BDNFI GENE; BDNFIIC GENE; BDNFIV GENE; BDNFVI GENE; BIPOLAR DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOWN REGULATION; FEMALE; GENE; GENE EXPRESSION; GENE LOCATION; GENETIC ANALYSIS; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; INTRACELLULAR SIGNALING; MAJOR DEPRESSION; MALE; NONHUMAN; PH; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; TRKB GENE; BRAIN; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; BIPOLAR DISORDER; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CORPUS STRIATUM; DEPRESSIVE DISORDER, MAJOR; FEMALE; HIPPOCAMPUS; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PREFRONTAL CORTEX; PROTEIN-TYROSINE KINASES; RNA, MESSENGER; SCHIZOPHRENIA;

EID: 84925614856     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.03.011     Document Type: Article

References (70)

1. Aid T., et al. Mouse and rat BDNF gene structure and expression revisited. J. Neurosci. Res. 2007, 85:525-535.
2. Andersen C.L., et al. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2004, 64:5245-5250.
3. Angelucci F., et al. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. J. Neurosci. Res. 2000, 60:783-794.
4. Angelucci F., et al. BDNF in schizophrenia, depression and corresponding animal models. Mol. Psychiatry 2005, 10:345-352.
5. Bai O., et al. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J. Neurosci. Res. 2003, 71:127-131.
6. Balu D.T., et al. Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments. Brain Res. 2008, 1211:37-43.
7. Barde Y.A. Trophic factors and neuronal survival. Neuron 1989, 2:1525-1534.
8. Barde Y.A. Neurotrophins: a family of proteins supporting the survival of neurons. Prog. Clin. Biol. Res. 1994, 390:45-56.
9. Benetti S., et al. Functional integration between the posterior hippocampus and prefrontal cortex is impaired in both first episode schizophrenia and the at risk mental state. Brain 2009, 132:2426-2436.
10. Calabrese F., et al. Chronic duloxetine treatment induces specific changes in the expression of BDNF transcripts and in the subcellular localization of the neurotrophin protein. Neuropsychopharmacology 2007, 32:2351-2359.
11. Chen B., et al. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol. Psychiatry 2001, 50:260-265.
12. Chlan-Fourney J., et al. Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration. Brain Res. 2002, 954:11-20.
13. Connor B., Dragunow M. The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res. Brain Res. Rev. 1998, 27:1-39.
14. Cross-Disorder Group of the Psychiatric Genomics, C., et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat. Genet. 2013, 45:984-994.
15. Davies A.M. Neurotrophic factors. Switching neurotrophin dependence. Curr. Biol. 1994, 4:273-276.
16. Dluzen D.E., et al. Striatal dopamine output is compromised within +/- BDNF mice. Synapse 2002, 43:112-117.
17. Durany N., et al. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr. Res. 2001, 52:79-86.
18. Dwivedi Y., et al. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch. Gen. Psychiatry 2003, 60:804-815.
19. French S.J., et al. Hippocampal neurotrophin and trk receptor mRNA levels are altered by local administration of nicotine, carbachol and pilocarpine. Brain Res. Mol. Brain Res. 1999, 67:124-136.
20. Fukumoto T., et al. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacol. (Berl.) 2001, 158:100-106.
21. Fumagalli F., et al. Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress. Int. J. Neuropsychopharmacol. 2012, 15:235-246.
22. Glausier J.R., et al. Lower glutamic acid decarboxylase 65-kDa isoform messenger RNA and protein levels in the prefrontal cortex in schizoaffective disorder but not schizophrenia. Biol. Psychiatry 2014, 77:167-176.
23. Gonzalez-Burgos G., et al. GABA neuron alterations, cortical circuit dysfunction and cognitive deficits in schizophrenia. Neural Plast. 2011, 2011:723184.
24. Haber S.N., Knutson B. The reward circuit: linking primate anatomy and human imaging. Neuropsychopharmacology 2010, 35:4-26.
25. Hashimoto T., et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J. Neurosci. 2003, 23:6315-6326.
26. Hashimoto T., et al. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J. Neurosci. 2005, 25:372-383.
27. Henseler I., et al. Disturbed functional connectivity within brain networks subserving domain-specific subcomponents of working memory in schizophrenia: relation to performance and clinical symptoms. J. Psychiatr. Res. 2010, 44:364-372.
28. Karege F., et al. Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res. Mol. Brain Res. 2005, 136:29-37.
29. Kenny P.J., et al. Acute nicotine decreases, and chronic nicotine increases the expression of brain-derived neurotrophic factor mRNA in rat hippocampus. Brain Res. Mol. Brain Res. 2000, 85:234-238.
30. Kim H.W., et al. Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients. Neurobiol. Dis. 2010, 37:596-603.
31. Korte M., et al. Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:8856-8860.
32. Korte M., et al. Virus-mediated gene transfer into hippocampal CA1 region restores long-term potentiation in brain-derived neurotrophic factor mutant mice. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:12547-12552.
33. Lanz T.A., et al. Robust changes in expression of brain-derived neurotrophic factor (BDNF) mRNA and protein across the brain do not translate to detectable changes in BDNF levels in CSF or plasma. Biomarkers 2012, 17:524-531.
34. Lauterborn J.C., et al. Differential effects of protein synthesis inhibition on the activity-dependent expression of BDNF transcripts: evidence for immediate-early gene responses from specific promoters. J. Neurosci. 1996, 16:7428-7436.
35. Lessmann V., et al. Neurotrophin secretion: current facts and future prospects. Prog. Neurobiol. 2003, 69:341-374.
36. Linnarsson S., et al. Learning deficit in BDNF mutant mice. Eur. J. Neurosci. 1997, 9:2581-2587.
37. Lipska B.K., et al. BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs. Eur. J. Neurosci. 2001, 14:135-144.
38. Liu I.Y., et al. Brain-derived neurotrophic factor plays a critical role in contextual fear conditioning. J. Neurosci. 2004, 24:7958-7963.
39. Liu Q.R., et al. Rodent BDNF genes, novel promoters, novel splice variants, and regulation by cocaine. Brain Res. 2006, 1067:1-12.
40. Ma Y.L., et al. Brain-derived neurotrophic factor antisense oligonucleotide impairs memory retention and inhibits long-term potentiation in rats. Neuroscience 1998, 82:957-967.
41. Malenka R.C., Bear M.F. LTP and LTD: an embarrassment of riches. Neuron 2004, 44:5-21.
42. Mannari C., et al. BDNF level in the rat prefrontal cortex increases following chronic but not acute treatment with duloxetine, a dual acting inhibitor of noradrenaline and serotonin re-uptake. Cell. Mol. Neurobiol. 2008, 28:457-468.
43. Martinowich K., Lu B. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology 2008, 33:73-83.
44. Mellios N., et al. Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia. Biol. Psychiatry 2009, 65:1006-1014.
45. Meyer-Lindenberg A., et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat. Neurosci. 2002, 5:267-271.
46. Meyer-Lindenberg A.S., et al. Regionally specific disturbance of dorsolateral prefrontal-hippocampal functional connectivity in schizophrenia. Arch. Gen. Psychiatry 2005, 62:379-386.
47. Miller B.H., et al. Genetic regulation of behavioral and neuronal responses to fluoxetine. Neuropsychopharmacology 2008, 33:1312-1322.
48. Nibuya M., et al. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J. Neurosci. 1995, 15:7539-7547.
49. Nurjono M., et al. A review of brain-derived neurotrophic factor as a candidate biomarker in schizophrenia. Clin. Psychopharmacol. Neurosci. 2012, 10:61-70.
50. Patterson S.L., et al. Recombinant BDNF rescues deficits in basal synaptic transmission and hippocampal LTP in BDNF knockout mice. Neuron 1996, 16:1137-1145.
51. Peng Q., et al. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Exp. Neurol. 2008, 210:154-163.
52. Porteous D.J., et al. The genetics and biology of DISC1-an emerging role in psychosis and cognition. Biol. Psychiatry 2006, 60:123-131.
53. Poulsen F.R., et al. Differential expression of brain-derived neurotrophic factor transcripts after pilocarpine-induced seizure-like activity is related to mode of Ca2+ entry. Neuroscience 2004, 126:665-676.
54. Ray M.T., et al. Decreased BDNF and TrkB mRNA expression in multiple cortical areas of patients with schizophrenia and mood disorders. Transl. Psychiatry 2014, 4:e389.
55. Rogoz Z., et al. Repeated treatment with mirtazepine induces brain-derived neurotrophic factor gene expression in rats. J. Physiol. Pharmacol. 2005, 56:661-671.
56. Sakata K., et al. Critical role of promoter IV-driven BDNF transcription in GABAergic transmission and synaptic plasticity in the prefrontal cortex. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:5942-5947.
57. Sakata K., et al. Role of activity-dependent BDNF expression in hippocampal-prefrontal cortical regulation of behavioral perseverance. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:15103-15108.
58. Schmidt H.D., Duman R.S. Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology 2010, 35:2378-2391.
59. Shimizu E., et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol. Psychiatry 2003, 54:70-75.
60. Shirayama Y., et al. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 2002, 22:3251-3261.
61. Sibille E., et al. GABA-related transcripts in the dorsolateral prefrontal cortex in mood disorders. Int. J. Neuropsychopharmacol. 2011, 14:721-734.
62. Siuciak J.A., et al. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol. Biochem. Behav. 1997, 56:131-137.
63. Takahashi M., et al. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol. Psychiatry 2000, 5:293-300.
64. Thompson Ray M., et al. Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J. Psychiatry Neurosci. 2011, 36:195-203.
65. Timmusk T., et al. Multiple promoters direct tissue-specific expression of the rat BDNF gene. Neuron 1993, 10:475-489.
66. Weickert C.S., et al. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol. Psychiatry 2003, 8:592-610.
67. Weickert C.S., et al. Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Mol. Psychiatry 2005, 10:637-650.
68. Wong J., et al. Promoter specific alterations of brain-derived neurotrophic factor mRNA in schizophrenia. Neuroscience 2010, 169:1071-1084.
69. Yasuda S., et al. The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol. Psychiatry 2009, 14:51-59.
70. Yin H.H., Knowlton B.J. The role of the basal ganglia in habit formation. Nat. Rev. Neurosci. 2006, 7:464-476.